Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Exact Sciences Soared 42.8% in January

By Cory Renauer - Updated Apr 26, 2019 at 4:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The diagnostics company's new marketing partner appears to be pulling its weight.

What happened

Shares of Exact Sciences (EXAS -3.77%), a cancer diagnostics company, gained 42.8% in January, according to data from S&P Global Market Intelligence. It looks like a marketing partnership with Pfizer (PFE -1.18%) is working better than expected.

So what

During the fourth quarter, Pfizer began helping Exact Sciences' sales team get its colorectal-cancer screening in front of more physicians and health systems, in return for a small share of the profits. Exact Sciences surged last month after reporting preliminary sales results that suggest Pfizer's contribution is worth the promotion fees.

Businessperson with a rocket on his back

Image source: Getty Images.

Nearly 15,000 healthcare providers ordered their first Cologuard test during the fourth quarter, which was a big improvement over the 11,000 new providers from whom Exact Sciences received first orders during the previous quarter. The number of tests completed also soared 21% compared to the previous quarter, to 292,000, and there's still plenty of room to grow.

Check out the latest Exact Sciences earnings call transcript.

Now what

Right now, just about everyone over the age of 55 in the U.S. can get a Cologuard test every three years, at a price of around $500 per test (which Medicare or their insurer has to cover completely). Test volume rose 64% to 934,000 last year, and with Pfizer's assistance, another big gain in 2019 seems likely.

Exact Sciences has been trading at 23.7 times trailing revenue, which should make anyone cautious. But with millions of potential customers, a heavy-hitting marketing partner, and an enormous potential customer base, it could be worth the risk.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
EXAS
$39.56 (-3.77%) $-1.55
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.27 (-1.18%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.